<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="119198">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01723670</url>
  </required_header>
  <id_info>
    <org_study_id>CCD-1109-PR-0072</org_study_id>
    <nct_id>NCT01723670</nct_id>
  </id_info>
  <brief_title>Evaluation of Effects of Multiple Dose Regimens of CHF 5074 on Potential Biomarkers of Neurodegeneration in Subjects With Mild Cognitive Impairment</brief_title>
  <acronym>CT05</acronym>
  <official_title>A Double-Blind, Randomized, Placebo-Controlled, Multicenter Study to Evaluate the Effects of Multiple Dose Regimens of CHF 5074 for up to 2 Years on Potential Biomarkers of Neurodegeneration in Subjects With Mild Cognitive Impairment</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Chiesi Pharmaceuticals Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Chiesi Pharmaceuticals Inc.</source>
  <oversight_info>
    <authority>United States: Food and Drug Administration</authority>
    <authority>United States: Institutional Review Board</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To evaluate the effects of multiple dose regimens of CHF 5074 administered once per day up
      to 2 years on potential biomarkers of neurodegeneration in subjects with mild cognitive
      impairment.
    </textblock>
  </brief_summary>
  <overall_status>Withdrawn</overall_status>
  <start_date>December 2012</start_date>
  <completion_date type="Anticipated">March 2016</completion_date>
  <primary_completion_date type="Anticipated">March 2016</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention</study_design>
  <primary_outcome>
    <measure>To determine the effects on change from baseline on brain atrophy</measure>
    <time_frame>pre-dose, Months 6, 12, 18, 24 and Washout</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>To determine the presence of other biomarkers of neuronal degeneration</measure>
    <time_frame>Day 1</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To determine the presence of other biomarkers of neuronal degeneration</measure>
    <time_frame>Month 24</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <other_outcome>
    <measure>Change from baseline in cognitive performance</measure>
    <time_frame>pre-dose, Month 6, Month 12, Month18, Month 24</time_frame>
    <safety_issue>No</safety_issue>
    <description>rate of cognitive decline</description>
  </other_outcome>
  <other_outcome>
    <measure>Change from baseline in global clinical status</measure>
    <time_frame>pre-dose, Month 6, Month 12, Month 18, Month 24</time_frame>
    <safety_issue>No</safety_issue>
  </other_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">0</enrollment>
  <condition>Alzheimer's Disease</condition>
  <arm_group>
    <arm_group_label>CHF 5074 1x</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>oral tablet, multidose</description>
  </arm_group>
  <arm_group>
    <arm_group_label>CHF 5074 2x</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>oral tablet, multidose</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>placebo, oral tablet, multidose</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>CHF 5074 1x</intervention_name>
    <description>oral tablet, 1x, once a day for 24 months</description>
    <arm_group_label>CHF 5074 1x</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>CHF 5074 2x</intervention_name>
    <description>oral tablet, 2x, once a day for 24 months</description>
    <arm_group_label>CHF 5074 2x</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>oral tablet,once a day for 24 months</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  One or two ∆ê4 alleles of the apolipoprotein E (APOE) gene.

          -  Diagnosis of amnestic Mild Cognitive Impairment.

          -  Mini-Mental State Examination score higher than 24 at screening.

        Exclusion Criteria:

          -  Diagnosis of Alzheimer's disease.

          -  Any medical condition that could explain the subject's cognitive deficits.

          -  MRI scans having evidence of pre-specified brain abnormalities.

          -  History of stroke.

          -  Vitamin B12 or folate deficiency.

          -  Skin cancers and any cancer that is being actively treated.

          -  Diagnosis of schizophrenia or recurrent mood disorder.

          -  Abnormal kidney function.

          -  Concomitant use of any study prohibitive medication.
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>45 Years</minimum_age>
    <maximum_age>64 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Joel S Ross, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Memory Enhancement Center of America</affiliation>
  </overall_official>
  <verification_date>November 2012</verification_date>
  <lastchanged_date>November 20, 2012</lastchanged_date>
  <firstreceived_date>October 31, 2012</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>Yes</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Alzheimer Disease</mesh_term>
    <mesh_term>Nerve Degeneration</mesh_term>
    <mesh_term>Cognition Disorders</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
